LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

AZN

185.74

-0.75%↓

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

AZN

185.74

-0.75%↓

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

AZN

185.74

-0.75%↓

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

AZN

185.74

-0.75%↓

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

AZN

185.74

-0.75%↓

Home・Aandelen Lijst・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Open

SectorGezondheidszorg

525.06 1.01

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

516.35

Max

533.74

Belangrijke statistieken
By Trading Economics
Inkomsten	-36M -94M
Verkoop	-9.7M 311M
EPS	-1.38
Winstmarge	-30.318
Werknemers	915
EBITDA	-43M -93M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+25.63% upside

Dividenden
By Dow Jones
Volgende Winsten	4 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-20M 12B
Vorige openingsprijs	524.05
Vorige sluitingsprijs	525.06

Nieuwssentiment

By Acuity

22%

78%

41 / 344 Rangschikking in Healthcare

Madrigal Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

26 mei 2026, 16:52 UTC

Belangrijke Nieuwsgebeurtenissen

NYMEX Overview: Brent Crude Futures Up; Iran Warns of Retaliation After US Strike -- OPIS

26 mei 2026, 23:57 UTC

Winsten

Sociedad Quimica 1Q Rev $1.76B >SQM

26 mei 2026, 23:57 UTC

Winsten

Sociedad Quimica 1Q EPS $1.28 >SQM

26 mei 2026, 23:48 UTC

Marktinformatie

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

26 mei 2026, 21:54 UTC

Winsten

Webco Industries 3Q EPS $11.61 >WEBC

26 mei 2026, 21:54 UTC

Winsten

Webco Industries 3Q Sales $179.6M >WEBC

26 mei 2026, 21:48 UTC

Marktinformatie

GE Aerospace's Repair Boom Should Last for Years -- Market Talk

26 mei 2026, 21:00 UTC

Marktinformatie

ESG Roundup: Market Talk

26 mei 2026, 20:58 UTC

Acquisities, Fusies, Overnames

Uber's $11.6 Billion Bid for DoorDash Rival Is About Future Proofing It From Robots -- Barrons.com

26 mei 2026, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

26 mei 2026, 20:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

26 mei 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

26 mei 2026, 19:22 UTC

Marktinformatie

Cryptocurrencies Add to Losses in Afternoon Trading -- Market Talk

26 mei 2026, 19:17 UTC

Marktinformatie

Oil Recovers Some Losses on U.S.-Iran Skirmishes -- Market Talk

26 mei 2026, 18:56 UTC

Marktinformatie

U.S. Natural Gas Futures Slip in Rangebound Trading -- Market Talk

26 mei 2026, 18:03 UTC

Marktinformatie

AutoCanada Faces Soft Demand, Slow Normalization -- Market Talk

26 mei 2026, 17:42 UTC

Marktinformatie

Grains Await Fresh Trading Catalyst -- Market Talk

26 mei 2026, 17:33 UTC

Marktinformatie

Salesforce, Snowflake Could Dispel Software Bear Thesis -- Market Talk

26 mei 2026, 17:21 UTC

Marktinformatie

Canada Faces a Labor Market Squeeze -- Market Talk

26 mei 2026, 16:52 UTC

Marktinformatie

Bonds to Fund Infrastructure for Data Centers Could Be Risky -- Market Talk

26 mei 2026, 16:43 UTC

Marktinformatie

Spotify's Latest Audio Play: Magazine Articles -- Market Talk

26 mei 2026, 16:24 UTC

Marktinformatie

Dollarama's LATAM Slowdown, Australia Costs Seen as Transient -- Market Talk

26 mei 2026, 16:21 UTC

Marktinformatie

Oil Extends Gains As Strikes Add Tension to U.S.-Iran Talks -- Market Talk

26 mei 2026, 16:20 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

26 mei 2026, 16:20 UTC

Marktinformatie

Energy & Utilities Roundup: Market Talk

26 mei 2026, 16:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

26 mei 2026, 16:20 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Auto & Transport Roundup: Market Talk

26 mei 2026, 16:16 UTC

Marktinformatie

Alberta Separation Threat Poses Headwind for Canada Dollar -- Market Talk

26 mei 2026, 16:01 UTC

Marktinformatie

Bitcoin Lower as Stress Builds for Holders -- Market Talk

26 mei 2026, 15:21 UTC

Marktinformatie

Hyperliquid Pushes Up to New All-Time High -- Market Talk

Peer Vergelijking

Prijswijziging

Madrigal Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

25.63% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 649.82 USD 25.63%

Hoogste 964 USD

Laagste 513.59 USD

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Madrigal Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Gebaseerd op 8 analisten die aandelenratings hebben gegeven aan Madrigal Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

41 / 344 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.